Vertebral cancellous tissueμCT parameters are not significantly affected by aging from 16 to 21 weeks, housing type, or microgravity. by Rukmani Cahill (20939813)

“…Nonsignificant trends implicate an effect of spaceflight reducing BV/TV, increasing DA, and reducing Tb.N. Data shown are the mean ±  standard deviation with a scatter plot (ns: non-significant). …”

<i>Oenocarpus bacaba</i> palm tree (A) and fruit (B). by Eudes Alves Simões-Neto (19697968)

“…Serological cure was achieved in 34.6% of cases, and IgG titers decreased in 15.3%.</p><p>Conclusions and significance</p><p>We encountered several barriers in managing ACD, including population vulnerability, reliance on outdated diagnostic techniques, lack of standardized molecular biology methods, and limited therapeutic options. …”

Epac activation increased MYPT phosphorylation via PLC/PKC. by Yoshiki Ohnuki (576298)

Opioid consumption data. by Wali U. Pirzada (22278071)

“…No significant difference was observed in the mean percentage of prescribed MMEs leftover between the two cohorts (Orthopaedic 47% vs. …”

Prescription data. by Wali U. Pirzada (22278071)

“…No significant difference was observed in the mean percentage of prescribed MMEs leftover between the two cohorts (Orthopaedic 47% vs. …”

Refill rate by surgical specialty. by Wali U. Pirzada (22278071)

“…No significant difference was observed in the mean percentage of prescribed MMEs leftover between the two cohorts (Orthopaedic 47% vs. …”

Noncontinuous data on opioid use. by Wali U. Pirzada (22278071)

“…No significant difference was observed in the mean percentage of prescribed MMEs leftover between the two cohorts (Orthopaedic 47% vs. …”

Phosphorylation status of myofilament proteins prepared from Epac1TG. by Yoshiki Ohnuki (576298)

Data Sheet 1_Exploring the glucose-lowering and anti-inflammatory immune mechanism of artemether by AMPK/mTOR pathway and microbiome based on multi-omics.docx by Tao Jiang (28401)

Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts. by Yoshiki Ohnuki (576298)

Epac activation increased RLC phosphorylation via PLC/PKC. by Yoshiki Ohnuki (576298)

SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort. by Amy J. Schuh (8520354)

KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort. by Amy J. Schuh (8520354)

Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts. by Amy J. Schuh (8520354)

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”